The problem of toxoplasmosis in outpatient practice. Part I. Toxoplasmosis in immunocompromised patients

Abstract

Toxoplasmosis remains one of the most common opportunistic infections in immunocompromised patients, primarily in people living with HIV. An increase in the number of requests for medical care by patients with HIV infection as the disease progresses determines the need for knowledge of outpatient therapists and general practitioners of decision-making algorithms for suspected toxoplasmosis in such patients. The main clinical manifestations of toxoplasmosis in patients with immunodeficiency states, the formulation of a preliminary diagnosis, and the routing algorithm are given.

Keywords

immunodeficiency / toxoplasmosis / HIV infection / outpatient doctor / family medicine

References

[1] Schlüter D, Barragan A. Advances and challenges in understanding cerebral toxoplasmosis. Front Immunol. 2019;10:(242):1–13. DOI: 10.3389/fimmu.2019.00242

[2] Schlüter D., Barragan A. Advances and challenges in understanding cerebral toxoplasmosis // Front. Immunol. 2019. Vol. 10, No. 242. P. 1–13. DOI: 10.3389/fimmu.2019.00242

[3] Wesołowski R, Pawłowska M, Smoguła M., Szewczyk-Golec K. Advances and challenges in diagnostics of toxoplasmosis in HIV-infected patients. Pathogens. 2023;12(110):1–13. DOI: 10.3390/pathogens12010110

[4] Wesołowski R., Pawłowska M., Smoguła M., Szewczyk-Golec K. Advances and challenges in diagnostics of toxoplasmosis in HIV-infected patients // Pathogens. 2023. Vol. 12, No. 110. P. 1–13. DOI: 10.3390/pathogens12010110

[5] Khan’ AV, Kalinina TN, Pan’kov AS, Tuchkov DYu. The structure of the causes of death of patients with hiv infection in 2018-2019 in the infectious hospital in Orenburg. Orenburg medical herald. 2021;9(4(36)):57–60. (In Russ.)

[6] Хань А.В., Калинина Т.Н., Паньков А.С., Тучков Д.Ю. Структура причин смерти пациентов с ВИЧ-инфекцией в 2018-2019 гг. в инфекционном стационаре г. Оренбурга // Оренбургский медицинский вестник. 2021. Т. 9, № 4(36). С. 57–60.

[7] Fernàndez-Sabé N, Cervera C, Fariñas MC, et al. Risk factors, clinical features, and outcomes of toxoplasmosis in solid-organ transplant recipients: a matched case-control study. Clin Infect Dis. 2012;54(3):355–361. DOI: 10.1093/cid/cir806

[8] Fernàndez-Sabé N., Cervera C., Fariñas M.C. et al. Risk factors, clinical features, and outcomes of toxoplasmosis in solid-organ transplant recipients: a matched case-control study // Clin. Infect. Dis. 2012. Vol. 54, No. 3. P. 355–361. DOI: 10.1093/cid/cir806

[9] Murakami D, Maki H, Matsuda K, et al. Cerebral toxoplasmosis complicating lymphoplasmacytic lymphoma in partial remission. J Infect Chemother. 2022;28(2):279–282. DOI: 10.1016/j.jiac.2021.09.005

[10] Murakami D., Maki H., Matsuda K. et al. Cerebral toxoplasmosis complicating lymphoplasmacytic lymphoma in partial remission // J. Infect. Chemother. 2022. Vol. 28, No. 2. P. 279–282. DOI: 10.1016/j.jiac.2021.09.005

[11] Dubey JP, Murata FHA, Cerqueira-Cézar CK, et al. Congenital toxoplasmosis in humans: an update of worldwide rate of congenital infections. Parasitology. 2021;148(12):1406–1416. DOI: 10.1017/S0031182021001013

[12] Dubey J.P., Murata F.H.A., Cerqueira-Cézar C.K. et al. Congenital toxoplasmosis in humans: an update of worldwide rate of congenital infections // Parasitology. 2021. Vol. 148, No. 12. P. 1406–1416. DOI: 10.1017/S0031182021001013

[13] Martin-Iguacel R, Ahlström MG, Touma M, et al. Incidence, presentation and outcome of toxoplasmosis in HIV infected in the combination antiretroviral therapy era. J Infect. 2017;75(3):263–273. DOI: 10.1016/j.jinf.2017.05.018

[14] Martin-Iguacel R., Ahlström M.G., Touma M. et al. Incidence, presentation and outcome of toxoplasmosis in HIV infected in the combination antiretroviral therapy era // J. Infect. 2017. Vol. 75, No. 3. P. 263–273. DOI: 10.1016/j.jinf.2017.05.018

[15] Connolly MP, Haitsma G, Hernández AV, Vidal JE. Systematic review and meta-analysis of secondary prophylaxis for prevention of HIV-related toxoplasmic encephalitis relapse using trimethoprim-sulfamethoxazole. Pathog Glob Health. 2017;111(6):327–331. DOI: 10.1080/20477724.2017.1377974

[16] Connolly M.P., Haitsma G., Hernández A.V., Vidal J.E. Systematic review and meta-analysis of secondary prophylaxis for prevention of HIV-related toxoplasmic encephalitis relapse using trimethoprim-sulfamethoxazole // Pathog. Glob. Health. 2017. Vol. 111, No. 6. P. 327–331. DOI: 10.1080/20477724.2017.1377974

[17] de Barros RAM, Torrecilhas AC, Marciano MAM, et al. Toxoplasmosis in human and animals around the world. Diagnosis and perspectives in the one health approach. Acta Trop. 2022;231:e:106432. DOI: 10.1016/j.actatropica.2022.106432

[18] de Barros R.A.M., Torrecilhas A.C., Marciano M.A.M. et al. Toxoplasmosis in human and animals around the world. Diagnosis and perspectives in the one health approach // Acta Trop. 2022. Vol. 231. P. e:106432. DOI: 10.1016/j.actatropica.2022.106432

[19] Almeria S, Dubey JP. Foodborne transmission of Toxoplasma gondii infection in the last decade. An overview. Res Vet Sci. 2021;135:371–385. DOI: 10.1016/j.rvsc.2020.10.019

[20] Almeria S., Dubey J.P. Foodborne transmission of Toxoplasma gondii infection in the last decade. An overview // Res. Vet. Sci. 2021. Vol. 135. P. 371–385. DOI: 10.1016/j.rvsc.2020.10.019

[21] Abbasi Fard S, Khajeh A, Khosravi A, et al. Fulminant and diffuse cerebral toxoplasmosis as the first manifestation of hiv infection: a case presentation and review of the literature. Am J Case Rep. 2020;21:e919624. DOI: 10.12659/AJCR.919624

[22] Abbasi Fard S., Khajeh A., Khosravi A. et al. Fulminant and diffuse cerebral toxoplasmosis as the first manifestation of hiv infection: a case presentation and review of the literature // Am. J. Case Rep. 2020. Vol. 21. P. e919624. DOI: 10.12659/AJCR.919624

[23] Dian S, Ganiem AR, Ekawardhani S. Cerebral toxoplasmosis in HIV-infected patients: a review. Pathog Glob Health. 2023;117(1):14–23. DOI: 10.1080/20477724.2022.2083977

[24] Dian S., Ganiem A.R., Ekawardhani S. Cerebral toxoplasmosis in HIV-infected patients: a review // Pathog. Glob. Health. 2023. Vol. 117, No. 1. P. 14–23. DOI: 10.1080/20477724.2022.2083977

[25] Makinson A, Park LS, Stone K, et al. Risks of opportunistic infections in people with human immunodeficiency virus with cancers treated with chemotherapy. Open Forum Infect Dis. 2021;8(8):1–8. DOI: 10.1093/ofid/ofab389

[26] Makinson A., Park L.S., Stone K. et al. Risks of opportunistic infections in people with human immunodeficiency virus with cancers treated with chemotherapy // Open Forum Infect. Dis. 2021. Vol. 8, No. 8. P. ofab389. DOI: 10.1093/ofid/ofab389

[27] Azoulay E, Russell L, Van de Louw A, et al. Diagnosis of severe respiratory infections in immunocompromised patients. Intensive Care Med. 2020;46(2):298–314. DOI: 10.1007/s00134-019-05906-5

[28] Azoulay E., Russell L., Van de Louw A. et al. Diagnosis of severe respiratory infections in immunocompromised patients // Intensive Care Med. 2020. Vol. 46, No. 2. P. 298–314. DOI: 10.1007/s00134-019-05906-5

[29] de-la-Torre A, Gómez-Marín J. Disease of the Year 2019: Ocular toxoplasmosis in HIV-infected patients. Ocul Immunol Inflamm. 2020;28(7):1031–1039. DOI: 10.1080/09273948.2020.1735450

[30] de-la-Torre A., Gómez-Marín J. Disease of the Year 2019: Ocular toxoplasmosis in HIV-infected patients // Ocul. Immunol. Inflamm. 2020. Vol. 28, No. 7. P. 1031–1039. DOI: 10.1080/09273948.2020.1735450

[31] Sudharshan S, Nair N, Curi A, et al. Human immunodeficiency virus and intraocular inflammation in the era of highly active antiretroviral therapy – an update. Indian J Ophthalmol. 2020;68(9):1787–1798. DOI: 10.4103/ijo.IJO_1248_20

[32] Sudharshan S., Nair N., Curi A. et al. Human immunodeficiency virus and intraocular inflammation in the era of highly active antiretroviral therapy – an update // Indian J. Ophthalmol. 2020. Vol. 68, No. 9. P. 1787–1798. DOI: 10.4103/ijo.IJO_1248_20

[33] Voznesenskiy SL, Shakhgildyan VI, Petrova EV, et al. Unspecified encephalitis in HIV-infected patients: clinical and postmortem evaluation. Terapevticheskii arkhiv. 2021;93(11):1278–1282. (In Russ.). DOI: 10.26442/00403660.2021.11.201197

[34] Вознесенский С.Л., Шахгильдян В.И., Петрова Е.В. и др. Энцефалиты неясной этиологии у больных ВИЧ-инфекцией: клиническая и патологоанатомическая расшифровка // Терапевтический архив. 2021. Т. 93, № 11. C. 1278–1282. DOI: 10.26442/00403660.2021.11.201197

[35] Washino T, Mikita K, Kosaka A, et al. Disseminated toxoplasmosis associated with haemophagocytic lymphohistiocytosis in a patient with the human immunodeficiency virus: a case report and literature review. Int J Infect Dis. 2022;123:176–179. DOI: 10.1016/j.ijid.2022.08.023

[36] Washino T., Mikita K., Kosaka A. et al. Disseminated toxoplasmosis associated with haemophagocytic lymphohistiocytosis in a patient with the human immunodeficiency virus: a case report and literature review // Int. J. Infect. Dis. 2022. Vol. 123. P. 176–179. DOI: 10.1016/j.ijid.2022.08.023

[37] Kitahara M, Hiroshima Y, Norose K, et al. Clinical characteristics and incidence of toxoplasmosis after autologous hematopoietic stem cell transplantation: a retrospective study and literature review. Transpl Infect Dis. 2021;23(6):e13726. DOI: 10.1111/tid.13726

[38] Kitahara M., Hiroshima Y., Norose K. et al. Clinical characteristics and incidence of toxoplasmosis after autologous hematopoietic stem cell transplantation: a retrospective study and literature review // Transpl. Infect. Dis. 2021. Vol. 23, No. 6. P. e13726. DOI: 10.1111/tid.13726

[39] Lee Loy J, Koratala A, De Los Santos Y, et al. Disseminated toxoplasmosis: a life-threatening complication of inadequate posttransplant prophylaxis. Kidney Int. 2019;95(5):1274. DOI: 10.1016/j.kint.2018.10.002

[40] Lee Loy J., Koratala A., De Los Santos Y. et al. Disseminated toxoplasmosis: a life-threatening complication of inadequate posttransplant prophylaxis // Kidney Int. 2019. Vol. 95, No. 5. P. 1274. DOI: 10.1016/j.kint.2018.10.002

[41] Wons J, Kempen J, Garweg JG. HIV-induced Retinitis. Ocul Immunol Inflamm. 2020;28(8):1259–1268. DOI: 10.1080/09273948.2020.1808225

[42] Wons J., Kempen J., Garweg J.G. HIV-induced Retinitis // Ocul. Immunol. Inflamm. 2020. Vol. 28, No. 8. P. 259–1268. DOI: 10.1080/09273948.2020.1808225

RIGHTS & PERMISSIONS

Eco-Vector